PT Pyridam Farma Tbk

IDX:PYFA Stock Report

Market Cap: Rp2.4t

Pyridam Farma Past Earnings Performance

Past criteria checks 0/6

Pyridam Farma's earnings have been declining at an average annual rate of -17.2%, while the Pharmaceuticals industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 28.2% per year.

Key information

-17.2%

Earnings growth rate

10.0%

EPS growth rate

Pharmaceuticals Industry Growth20.4%
Revenue growth rate28.2%
Return on equity-20.5%
Net Margin-18.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Pyridam Farma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

IDX:PYFA Revenue, expenses and earnings (IDR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,343,423-246,239412,4530
30 Jun 24795,775-142,375354,0170
31 Mar 24740,866-119,829331,4020
31 Dec 23702,068-85,221303,1470
30 Sep 23684,977-66,728283,3800
30 Jun 23721,928229,504313,6000
31 Mar 23707,846260,664294,2820
31 Dec 22715,425275,241286,4330
30 Sep 22775,078278,272287,735-573
30 Jun 22715,1323,165245,8190
31 Mar 22685,557-2,877235,1430
31 Dec 21630,5305,479219,9770
30 Sep 21488,49621,948175,207573
30 Jun 21378,33527,773147,7430
31 Mar 21315,77728,590133,4480
31 Dec 20277,39822,104134,3400
30 Sep 20257,67420,539140,3480
30 Jun 20247,32113,275131,8530
31 Mar 20262,33111,823136,4960
31 Dec 19247,1159,343129,2820
30 Sep 19249,6449,070133,9950
30 Jun 19248,9138,505133,8320
31 Mar 19249,4058,697136,5890
31 Dec 18250,4468,447137,3790
30 Sep 18240,1276,303131,0810
30 Jun 18239,2677,604131,6010
31 Mar 18235,9447,453128,6120
31 Dec 17223,0027,127122,5230
30 Sep 17225,2937,431124,2470
30 Jun 17210,1353,729118,4280
31 Mar 17215,8735,508124,4240
31 Dec 16216,9525,146124,2390
30 Sep 16217,3935,210125,1920
30 Jun 16221,9164,383127,3400
31 Mar 16215,0162,909124,1660
31 Dec 15217,8443,087127,5800
30 Sep 15220,0712,953131,8140
30 Jun 15224,6023,495136,3490
31 Mar 15221,2102,112133,6770
31 Dec 14222,3022,661132,1640
30 Sep 14218,8974,334127,2830
30 Jun 14217,3125,149129,7400
31 Mar 14203,5056,323125,2280

Quality Earnings: PYFA is currently unprofitable.

Growing Profit Margin: PYFA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PYFA is unprofitable, and losses have increased over the past 5 years at a rate of 17.2% per year.

Accelerating Growth: Unable to compare PYFA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PYFA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4%).

Return on Equity

High ROE: PYFA has a negative Return on Equity (-20.54%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 17:57
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PT Pyridam Farma Tbk is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elvira NataliaPT Sinarmas Sekuritas